Sutro Biopharma, Inc. (STRO) financial statements (2021 and earlier)

Company profile

Business Address 310 UTAH AVE., SUITE 150
SOUTH SAN FRANCISCO, CA 94080
State of Incorp.
Fiscal Year End December 31
SIC 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments368118204
Cash and cash equivalents2065125
Short-term investments16211379
Receivables673
Other undisclosed current assets432
Total current assets:378129210
Noncurrent Assets
Property, plant and equipment131011
Long-term investments and receivables 16 
Long-term investments 16 
Restricted cash and investments100
Other noncurrent assets232
Total noncurrent assets:162813
TOTAL ASSETS:394156223
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities14129
Accounts payable663
Accrued liabilities966
Deferred revenue1519
Debt 15
Contract with customer, liability22
Other liabilities111
Total current liabilities:303336
Noncurrent Liabilities
Long-term debt and lease obligation25910
Long-term debt, excluding current maturities25910
Liabilities, other than long-term debt81745
Deferred revenue616
Contract with customer, liability45
Deferred rent credit100
Other liabilities000
Total noncurrent liabilities:322655
Total liabilities:625992
Stockholders' equity
Stockholders' equity attributable to parent33298132
Common stock000
Additional paid in capital560293282
Accumulated other comprehensive income (loss)00(0)
Accumulated deficit(228)(196)(150)
Total stockholders' equity:33298132
TOTAL LIABILITIES AND EQUITY:394156223

Income statement (P&L) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
Revenue from related parties323 
Gross profit:434338
Operating expenses(114)(98)(76)
Operating loss:(71)(55)(37)
Nonoperating income244
Investment income, nonoperating242
Other nonoperating income  2
Interest and debt expense(2)(1)(2)
Loss from continuing operations before income taxes:(72)(52)(35)
Income tax expense(0)  
Loss before gain (loss) on sale of properties:(72)(52)(35)
Other undisclosed net income (loss)40(3) 
Net loss available to common stockholders, diluted:(32)(56)(35)

Comprehensive Income ($ in millions)

12/31/2020
12/31/2019
12/31/2018
Net loss:(32)(56)(35)
Comprehensive loss:(32)(56)(35)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(0)0(0)
Comprehensive loss, net of tax, attributable to parent:(32)(56)(35)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: